71 patents
Utility
Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor
9 Jan 24
The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma.
Renier J. Brentjens, Eric L Smith, Cheng Liu
Filed: 21 Feb 20
Utility
Constructs trageting CD22 and uses thereof
28 Nov 23
Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof).
Jun Cui, Pengbo Zhang, Yiyang Xu, Shan Li, Yixiang Xu, Guangyan Xiong, Hongruo Yun, Lianxing Liu, Xiaomei Ge, Shaohua Xu, Hong Liu, Javier Morales
Filed: 29 Mar 19
Utility
Compositions Targeting NDC80/MHC Complexes and Uses Thereof
23 Nov 23
The present technology relates generally to compositions that specifically recognize and bind to a NDC80 peptide complexed with a major histocompatibility antigen (e.g., HLA-A*02).
Martin KLATT, Tao DAO, David A. SCHEINBERG, Zhiyuan YANG, Jianying LIU
Filed: 8 Oct 21
Utility
Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
21 Nov 23
The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma.
Renier J. Brentjens, Eric L. Smith, Cheng Liu
Filed: 21 Feb 20
Utility
T Cells and Chimeric Stimulating Receptors and Uses Thereof
21 Sep 23
Described herein are immune cells comprising: a T-cell receptor (TCR) and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain.
Cheng Liu, Hongbing Zhang, Zhiyuan Yang, Pengbo Zhang, Yixiang Xu, Guangyuan Xiong, Ziyou Cui
Filed: 29 Jul 21
Utility
Antibodies targeting B-cell maturation antigen and methods of use
15 Aug 23
The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
Renier J. Brentjens, Eric L. Smith, Cheng Liu
Filed: 11 Feb 21
Utility
Chimeric antibody/T-cell receptor constructs and uses thereof
28 Mar 23
The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling molecule.
Lucas Horan, Yiyang Xu, Zhiyuan Yang, Hong Liu, Javier Morales, Lianxing Liu
Filed: 24 Apr 18
Utility
Constructs Specifically Recognizing Glypican 3 and Uses Thereof
16 Feb 23
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3.
Pengbo ZHANG, Yiyang Xu, Javier Morales, Yoko Nakano, Hong Liu, Jingyi Xiang, Timothy Acker
Filed: 3 Aug 22
Utility
Nucleic acid molecules encoding anti-GPRC5D antibodies
31 Jan 23
The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
Renier J. Brentjens, Eric L. Smith, Cheng Liu
Filed: 31 Dec 19
Utility
Chimeric Antigen Receptors Targeting FC Receptor-like 5 and Uses Thereof
19 Jan 23
The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma).
Renier J. Brentjens, Eric L. Smith, Cheng Liu
Filed: 27 May 21
Utility
T cell receptor-like antibodies specific for Foxp3-derived peptides
22 Nov 22
The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex.
David A. Scheinberg, Tao Dao, Cheng Liu
Filed: 13 Jan 17
Utility
Antibody/t-cell Receptor Chimeric Constructs and Uses Thereof
3 Nov 22
The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module.
Jingwei LU, Zhiyuan YANG, Cheng LIU, Hong LIU, Yiyang XU, Su YAN, Vivien Wai-Fan CHAN, Lucas HORAN
Filed: 8 Apr 22
Utility
Cells Expressing Chimeric Antigen Receptors and Chimeric Stimulating Receptors and Uses Thereof
13 Oct 22
Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain.
Hongruo YUN, Jun Cui, Pengbo Zhang, Yiyang Xu, Lucas Horan, Shaohua Xu, Guangyan Xiong, Shan Li, Yixiang Xu, Bradley Austin Heller, Hongbing Zhang, Hong Liu
Filed: 24 Jul 20
Utility
Antibodies Targeting B-cell Maturation Antigen and Methods of Use
6 Oct 22
The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
Renier J. Brentjens, Eric L. Smith, Chen Liu
Filed: 11 Feb 21
Utility
Constructs specifically recognizing glypican 3 and uses thereof
20 Sep 22
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3.
Pengbo Zhang, Yiyang Xu, Javier Morales, Yoko Nakano, Hong Liu, Jingyi Xiang, Timothy Acker
Filed: 24 Apr 18
Utility
FOXP3 Targeting Agent Compositions and Methods of Use for Adoptive Cell Therapy
25 Aug 22
Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising (a) an engineered receptor, vector encoding an engineered receptor, or engineered immune cell expressing such engineered receptor or comprising such vector; and (b) a Fox P3 targeting agent.
David A. SCHEINBERG, Cheng LIU, Zhiyuan YANG, Lianxing LIU, Shaohua Xu, Pei WANG, Yiyang XU
Filed: 14 Feb 19
Utility
Chimeric Antigen Receptor T Cells and Uses Thereof
25 Aug 22
Described herein are chimeric antigen receptors (CARs) comprising an extracellular target-binding domain comprising an antibody moiety (e.g., a single chain variable fragment (scFv) antibody), a transmembrane domain, a CD30 costimulatory domain, and a primary signaling domain.
Hongruo YUN, Jun Cui, Pengbo Zhang, Yiyang Xu, Lucas Horan, Shaohua Xu, Guangyan Xiong, Shan LI, Yixiang Xu, Hong Liu
Filed: 24 Jul 20
Utility
Antibody/T-cell receptor chimeric constructs and uses thereof
23 Aug 22
The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module.
Jingwei Lu, Zhiyuan Yang, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan, Vivien Wai-Fan Chan, Lucas Horan
Filed: 21 Oct 16
Utility
Humanized Antibodies to MUCIN-16 and Methods of Use Thereof
28 Jul 22
Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16).
David SPRIGGS, Dharmarao THAPI, Su YAN, Cheng LIU
Filed: 7 May 20
Utility
T cell receptor-like antibodies specific for a PRAME peptide
12 Jul 22
The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof.
David A. Scheinberg, Tao Dao, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan
Filed: 20 Nov 17